Sapere Bio is a diagnostic company in a clinical stage of development. We measure signatures of aging which are then developed into clinical risk prediction tools to predict patient's risk for adverse events in cardiology, nephrology, oncology, and neurology. Our highly differentiable products address critical and unmet medical need and allow risk, inherent to the patient, to be quantified. Accurate risk stratification before procedures and therapies will improve patients’ quality of life, decrease disability and mortality, and cut healthcare costs. Sapere Bio was co-founded by Dr. Norman Sharpless at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine-Chapel Hill and Dr Natalia Mitin, current CEO of Sapere Bio.